Home > Capabilities > Manufacturing
Manufacturing
Biocon Biologics runs world-class manufacturing facilities in India and Malaysia to serve global healthcare needs at scale and speed. Our India sites include the largest facility in India dedicated to manufacturing monoclonal antibodies (mAbs). Our Johor, Malaysia plant is Asia’s largest integrated insulin manufacturing site — a global center of excellence that strengthens access to affordable insulins.
We have established expertise across microbial and mammalian platforms to produce a broad portfolio of insulins, mAbs and conjugated recombinant proteins.
We drive operational excellence through vertical integration, lean processes, and data analytics. Our facilities consistently meet the highest regulatory standards, with approvals from the U.S. Food and Drug Administration, European Medicines Agency (EMA), ANSM (France), HPRA (Ireland), ANVISA (Brazil), NPRA (Malaysia), Ministry of Health (Russia), MFDS (South Korea) and several others.
We also collaborate with trusted manufacturing partners worldwide, extending our reach and resilience.
Industry 4.0 technologies enhance our efficiency, agility and future readiness. These capabilities allow us to deliver high-quality biosimilars that address critical unmet medical needs across the globe.
Global Manufacturing Network for Drug Product Facilities
Drivers of Change